I'm not worried at all by the dip, pretty much status quo. 4...

I'm not worried at all by the dip, pretty much status quo. 4 days of 'trading' in the past 2 weeks...


.....................volume......value
20/08/13........76,133......$12,600
26/08/13........48,500......$7,990
29/08/13........10,000......$1,612
02/09/13........18,000......$2,822

Total...........152,633.......$25,024

Hardly a huge vote either way. Until the issuance is done and dusted I can't see liquidity and interest in MLA picking up. Medivet US has huge potential, but it will remain to be seen whether MLA overpaid and whether Medivet hits the ambitious projections outlined in the merger docs.

Positives IMO are the reasonable escrow terms, the tight top 25 holders, additional funds to improve the OEM business and marketing, ALT Burette licensing, combined with the review of business (clements)in the recent update - which will likely be sold decreasing costs, employee numbers and bringing the OEM business close to breakeven.

So I still feel its a LT Buy. And will happily pick up more from anyone who wants out at sub 10c!